{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.4","upperLimit":"28.1","value":"13.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"For patients enrolled on the high-risk arm with measurable residual disease after induction treated with consolidation therapy, we will estimate the objective response (complete response (CR)/partial response (PR)) rate after consolidation therapy with a 95% confidence interval. Objective responses must be sustained for at least eight weeks. All patients who receive at least 1 dose of cyclophosphamide or topotecan during consolidation are evaluable for response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG000","title":"High-Risk Group"}],"paramType":"NUMBER","populationDescription":"Of the 50 high-risk patients that started consolidation chemotherapy, 38 had measurable residual disease after induction and were included in this result.","reportingStatus":"POSTED","timeFrame":"8 weeks after completion of consolidation therapy (up to 8 months after on-study date)","title":"Percent of Patients With Sustained Objective Responses Rate After Consolidation","type":"SECONDARY","unitOfMeasure":"percentage of participants"}